Cardiff Oncology: Paramount Data Imminent In Huge First-Line mCRC Market [Seeking Alpha]
Cardiff Oncology, Inc. (CRDF)
Company Research
Source: Seeking Alpha
21min Summary Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated metastatic colorectal cancer, potentially opening a massive market with an estimated $567 million to $3.78 billion in annual US sales. Onvansertib has demonstrated superior efficacy and safety over historical controls and competitors, particularly in bevacizumab-naïve patients, with impressive objective response rates and progression-free survival. Positive data from the ongoing CRDF-004 trial could lead to significant upside for Cardiff, attracting potential partnerships or acquisition interest from big pharma, including Pfizer. Cardiff's strong financial position, low cash burn, and favorable analyst ratings make it a compelling buy, with substantial growth potential in the mCRC market and beyond. Mohammed Haneefa Nizamudeen/iStock via Getty Images Thesis Any day now, Cardiff ( NASDAQ: CRDF ) may announce objective response rate data of its Phase 2 trial for the first-line treatment o
Show less
Read more
Impact Snapshot
Event Time:
CRDF
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRDF alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRDF alerts
High impacting Cardiff Oncology, Inc. news events
Weekly update
A roundup of the hottest topics
CRDF
News
- Cancer Care Disruptions Highlight Growing Demand for Innovative Oncology Treatments [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Cardiff Oncology, Inc. (NASDAQ: CRDF) had its price target raised by analysts at Piper Sandler from $7.00 to $10.00. They now have an "overweight" rating on the stock.MarketBeat
- Cardiff Oncology announces positive colorectal data and $40m stock oversubscription [Yahoo! Finance]Yahoo! Finance
- Biotech Stock Roundup: BIOA Down on Study Update, QURE, CRDF Gain on Study Data & More [Yahoo! Finance]Yahoo! Finance
- CRDF Stock Soars on Robust Efficacy Data From Colorectal Cancer Study [Yahoo! Finance]Yahoo! Finance
CRDF
Earnings
- 11/7/24 - Beat
CRDF
Sec Filings
- 12/18/24 - Form 4
- 12/17/24 - Form SCHEDULE
- 12/16/24 - Form 4
- CRDF's page on the SEC website